Xencor Inc 2020 SR
The report outlines Xencor's commitment to corporate responsibility and the formalization of its ESG program in 2021. Key highlights from 2020 include a 43% increase in research and development spending and a 22% growth in the workforce to 202 full-time employees. The company emphasizes diversity, with women representing 55% of the total workforce and 25% of the Board of Directors. Additionally, Xencor highlights its ethical approach to clinical trials and preclinical testing, as well as its community partnership with the Leukemia & Lymphoma Society.
Company: Xencor Inc
Sector: Health Care
Country: United States
Year: 2020
Type: SR
Pages: 4
Xencor Inc
Corporate Responsibility Statement
The report outlines Xencor's commitment to corporate responsibility and the formalization of its ESG program in 2021. Key highlights from 2020 include a 43% increase in research and development spending and a 22% growth in the workforce to 202 full-time employees. The company emphasizes diversity, with women representing 55% of the total workforce and 25% of the Board of Directors. Additionally, Xencor highlights its ethical approach to clinical trials and preclinical testing, as well as its community partnership with the Leukemia & Lymphoma Society.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
Apr 1, 2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees